MRS of 2-hydroxyglutarate (2HG) has the great potential for determining the isocitrate dehydrogenase (IDH) mutational status in brain tumors noninvasively. This clinical role of 2HG MRS may be demonstrated most clearly in patients with brainstem gliomas or deep brain lesions, where surgical biopsy presents significant risk of permanent neurological deficit. We report 2HG MRS data in patients with brainstem tumors. 2HG was evaluated, using a 2HG-optimized TE 97ms PRESS at 3T, in 12 subjects with brainstem lesions in vivo. We also presents data of monitoring the tumor with serial 2HG MRS scans.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords